Literature DB >> 18941407

Mycobacterium bovis infection of an axillary-femoral bypass graft after intravesical bacille Calmette-Guérin immunotherapy for bladder cancer.

Faiz Shakir1, Van Dang, Michael S Bronze, Cheng Liu, Linda Machado.   

Abstract

We report a case of bacillus Calmette-Guérin (BCG) infection of an axillary-femoral bypass graft presenting approximately 10 months after the initiation of intravesicular bacillus Calmette-Guérin for the treatment of bladder cancer. The patient's clinical course included removal of the bypass graft and antimycobacterial treatment with isoniazid, rifampin, and ethambutol for 9 months.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 18941407     DOI： 10.1097/01.MAJ.0000308884.50320.8a

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN： 0002-9629            Impact factor:   2.378


  3 in total

Review 1.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

2.  Infection of an axillo-bifemoral bypass graft following intravesical bacillus Calmette-Guerin (BCG) immunotherapy for urothelial cancer due to Mycobacterium bovis and Staphylococcus aureus.

Authors:  Daniel C DeSimone; Aaron J Tande
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2016-09-16

3.  Mycobacterium bovis infection of a femorofemoral bypass graft following intravesical Bacillus Calmette-Guérin (BCG) immunotherapy.

Authors:  Ryan K Meyer; Stephen J Williams; Thomas Y Lee
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2020-02-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.